Verily Pre will connect PacBio HiFi Sequencing with governed cloud analysis, multimodal health data and AI-ready research ...

PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2026 ...

The average one-year price target for Pacific Biosciences of California (BMV:PACB) has been revised to MX$48.04 / share. This is an increase of 25.34% from the prior estimate of MX$38.33 dated October ...

Pacific Biosciences of California (PACB) closed at $2.06 in the latest trading session, marking a -3.74% move from the prior day. This change lagged the S&P 500's daily loss of 1.21%. On the other ...

Pacific Biosciences of California's business model struggles to gain traction versus larger, profitable competitors like ...

PacBio and AI drug discovery company TychoBio are generating full-length RNA datasets from more than 10,000 samples to train ...

Now that Pacific Biosciences has broken through the $1 level that avoids Nasdaq delisting for now, we can focus on what might be ahead: the near-term path to cash flow breakeven. PacBio’s biggest ...

Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.

MENLO PARK, Calif. and PARIS, Oct. 06, 2026 (GLOBE NEWSWIRE)-- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and TychoBio, an AI drug discovery company, today ...

Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 29.7% in the afternoon session after EpiSign announced the launch of EpiSign METRIC 5-base, enabling laboratories to ...